New imaging combo could sharpen prostate cancer radiation
NCT ID NCT03734757
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether combining PET-CT and MRI scans (called trimodality imaging) can better define the target area for radiotherapy in high-risk prostate cancer. Twenty patients received both standard scans and the new combined scan before treatment. Researchers compared the volumes drawn for radiation planning to see if the new method changes the treatment approach.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this imaging approach could help doctors more precisely target radiotherapy for high-risk prostate cancer, potentially improving outcomes.
- What could go wrong
- This is a very small, early study (20 participants) focused on imaging comparisons, not treatment outcomes. It may not lead to changes in standard care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Centre Henri Becquerel
Rouen, 76038, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new tracer light up hidden prostate cancer?
- Could deep breaths before surgery ward off Post-Op confusion?
- A second look: MRI screening may spot hidden prostate cancers
- Can precision protons spare the bowel in prostate cancer?
- AI coaches doctors on cancer risk talks
- Can an immune booster make hormone therapy work better against prostate cancer?